Melanoma cell lines derived from patients and induced into a mesenchymal state Via TGF-β treatment show resistance to BRAF inhibitors like vemurafenib but are sensitive to the ferroptosis inducer RSL3 [79]. Here, BRAF is linked to melanoma.